Drug Profile
GRN 1201
Alternative Names: GRN-1201Latest Information Update: 18 Aug 2023
Price :
$50
*
At a glance
- Originator GreenPeptide
- Developer BrightPath Biotherapeutics
- Class Antineoplastics; Cancer vaccines; Peptide vaccines; Peptides
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Non-small cell lung cancer
- No development reported Malignant melanoma
Most Recent Events
- 08 Aug 2023 BrightPath Biotherapeutics due to slow recruitment terminated a phase II trial for Non-small cell lung cancer (Combination therapy, First-line therapy, Metastatic disease, Second-line therapy) in USA (NCT03417882)
- 28 Apr 2023 No recent reports of development identified for phase-I development in Malignant-melanoma in USA (Intradermal, Injection)
- 06 Apr 2021 Phase II trial is still ongoing for Non-small cell lung cancer (Combination therapy, First-line therapy, Metastatic disease, Second-line therapy) in USA (NCT03417882)